Wanhua in Polyisocyanates Cooperation with Sapici

China’s Wanhua Chemical Group has entered into a distribution and tolling collaboration with Italy’s Sapici for aliphatic polyisocyanates.

Under the terms of the agreement, Sapici will warehouse and distribute Wanhua’s product range throughout Europe, the Middle East and Africa. Wanhua will also have access to Sapici’s manufacturing capacities and technical resources.

A manufacturer and marketer of raw materials for coatings and adhesives, Sapici has three production plants – two in Italy at Cernusco sul Naviglio, Milan, and San Cipriano Po, Pavia, and one in Zhuhai, Guangdong, China. The company invested a multi-million euro sum last year to expand capacity in San Cipriano Po and Zhuhai.

Christian Furiosi, Sapici’s CEO, said the partners will leverage the recent investment in isocyanate production and will continue to expand their portfolio.

Wanhua claims to be the largest MDI manufacturer in the world and the only Chinese company with independent intellectual property rights for making methylene diphenyl diisocyanate (MDI), hexamethylene diisocyanate (HMDI), and isophorone diisocyanate (IPDI).

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.